1
Melvin E Clouse: Method and device for performing endovascular repair of aneurysms. New England Deaconess Hospital Corporation, Fish & Richardson, May 18, 1993: US05211658 (340 worldwide citation)

A blood vessel wall-defining device and method for using the device for repairing an aneurysm. The device comprises in combination, a percutaneously-insertable structural frame extending between first and second ends having an unexpanded diameter which is smaller than the diameter of the blood vesse ...


2
Victor Gurewich: Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases. New England Deaconess Hospital Corporation, Fish & Richardson P C, June 2, 1998: US05759542 (91 worldwide citation)

A fusion drug including an isolated portion of the A-chain of a urokinase-type plasminogen activator linked to a drug, wherein the A-chain portion binds stably to an outer membrane of a platelet. The T.sub.1/2 of the fusion drug in plasma is thereby increased to about 4 to 5 days, and the fusion dru ...


3
Regina K Stuart, Jeffrey A Lowell, John K Baxter III, Bruce R Bistrian, Scott Shikora: Method for central venous catheterization. New England Deaconess Hospital Corporation, May 19, 1992: US05114401 (73 worldwide citation)

Disclosed are an apparatus and methods for initial, or replacement, central venous catherization using a flexible guidewire with markings thereon and a substantially translucent non-thrombogenic catheter. In operation, the guidewire is inserted along a catheter positioned in a vein. The marks on the ...


4
Ralph K Ito, Frank W LoGerfo: Biocompatible substance with thromboresistance. New England Deaconess Hospital Corporation, Lahive & Cockfield, May 28, 1991: US05019393 (71 worldwide citation)

Disclosed is a biocompatible, thromboresistant substance useful for implantable and extracorporeal devices in contact with the vascular system, and methods for producing the same. The biocompatible, thromboresistant substance comprises a synthetic, biocompatible material, at least one biocompatible ...


5
Robert S Lees, Ann M Lees, Allan Fischman, Ing Lung Shih, Mark A Findeis: Synthetic peptides for arterial imaging. New England Deaconess Hospital Corporation, Clark & Elbing, October 26, 1999: US05972890 (71 worldwide citation)

Vascular disease including asymptomatic atherosclerosis can be diagnosed by administering a synthetic peptide or peptide analog having an affinity for, and propensity to accumulate at, a site of vascular injury to a patient, and then detecting the location of the peptide or peptide analog within the ...


6
Ralph K Ito, Frank W LoGerfo: Hirudin-coated biocompatible substance. New England Deaconess Hospital Corporation, Lahive & Cockfield, December 1, 1992: US05167960 (57 worldwide citation)

Disclosed is a biocompatible, thromboresistant substance useful for implantable and extracorpeoreal devices in contact with the vascular system, and methods for producing the same. The biocompatible, thromboresistant substance comprises a synthetic, biocompatible material, at least one biocompatible ...


7
Bruce R Bistrian, Vigen K Babayan, George L Blackburn, Edward A Mascioli: Dietary supplement utilizing .omega.-3/medium chain trigylceride mixtures. New England Deaconess Hospital Corporation, Lahive & Cockfield, October 3, 1989: US04871768 (42 worldwide citation)

A new dietary supplement has been developed which yields the benefits of both .omega.3 oils and medium chain triglycerides for lipid nutrition. A structured lipid containing .omega.3 fatty acids and medium chain fatty acids is also disclosed.


8
Robert S Lees: Detection of vascular disease with labelled antibodies. New England Deaconess Hospital Corporation, Lahive & Cockfield, October 31, 1989: US04877599 (37 worldwide citation)

Vascular diseases including asymptomatic atherosclerosis can be diagnosed by administering a conjugate diagnostic reagent to a patient and then detecting the location and concentration of the conjugate reagent within the patient's vascular system. The conjugate reagents have a target-seeking, biolog ...


9
Carol A Toth, Peter Thomas: Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses. New England Deaconess Hospital Corporation, Lahive & Cockfield, April 3, 1990: US04914021 (35 worldwide citation)

Disclosed is a glycoprotein, carcinoma orosomucoid-related antigen, (CORA), which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and can be characteried by having a molecular weight of about 46,000-50,000 daltons, an isoelectric point of about ...


10
Ronald R Salem, Peter Thomas, Glenn Steele: Marker for colorectal carcinoma and methods of detecting the same. New England Deaconess Hospital Corporation, Lahive & Cockfield, May 1, 1990: US04921789 (31 worldwide citation)

A new marker for colorectal carcinoma has been discovered which is a glycoprotein having a molecular weight of approximately 160,000 daltons. Assay methods which can identify this marker are useful indetecting, diagnosing, and monitoring colorectal carcinoma, and in particular, carcinoma of the undi ...